Clinical Trial Search

Phase 3 N=487 Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan

Rheumatoid Arthritis

Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) — 371; 105; 476; 111 Particiants

Pfizer Results May 2015 28.6% serious AE View details

Phase 3 N=94 Treatment Strategy to Prevent Mood Disorders Following Traumatic Brain Injury

Traumatic Brain Injury

Primary: Time to Onset of Diagnostic and Statistical Manual (DSM) IV Defined Mood and Anxiety Disorders Associated With Traumatic Brain Injury (TBI) — 21.4264; 15.7833 weeks…

Baylor College of Medicine Results May 2015 2.1% serious AE View details

Phase 3 N=133 Efficacy Study of Ambrisentan in Chinese Patients With Pulmonary Arterial Hypertension (PAH)

Vascular Disease

Primary: Change From Baseline in 6-minutes Walk Test (6MWT) at Week 12 — 53.59 Meters — p=<0.001

GlaxoSmithKline Results May 2015 8.2% serious AE View details

Phase 3 N=982 An Evaluation of the Safety and Efficacy of Moxifloxacin Ophthalmic Solution 0.5% ((VIGAMOX®) Versus Ofloxacin Ophthalmic Solution 0.3% in the Treatment of Bacterial Conjunctivitis in Chinese Patients

Bacterial Conjunctivitis

Primary: Clinical Cure Rate — 85.4; 81.4 percentage of participants

Alcon Research Results May 2015 0.1% serious AE View details

Phase 3 N=216 Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)

Alzheimer's Disease

Primary: Percentage of Patients With Adverse Events Leading to Study Drug Discontinuation — 15; 18.5 Percentage of participants

Novartis Pharmaceuticals Results May 2015 8.8% serious AE View details

Phase 3 N=162 Adjuvant Chemotherapy in Treating Women Who Have Undergone Resection for Relapsed Breast Cancer; Chemotherapy as Adjuvant for LOcally Recurrent Breast Cancer

Breast Cancer

Primary: Disease-free Survival — 57; 69 percentage of participants

ETOP IBCSG Partners Foundation Results May 2015 7.4% serious AE View details

Phase 3 N=148 Safety and Immunogenicity of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) in Healthy Female Children 4-6 Years Old

Infections, Papillomavirus

Primary: Number of Subjects With Any and Grade 3 Solicited Local Symptoms — 45; 15; 2; 0 Participants

GlaxoSmithKline Results May 2015 2.0% serious AE View details

Phase 3 N=229 Nitrates and Bone Turnover; Nitrates and Bone Turnover Bisphosphonate Sub-Study

Osteoporosis

Primary: Bone Turnover Markers — -4.627; -0.405; -4.297; -6.126 Percent change from baseline

University of Toronto Results May 2015 0.9% serious AE View details

Phase 3 N=44 Switching Study of Kidney Transplant Patients With Tremor to LCP-Tacro (STRATO)

Renal Failure · Tremors

Primary: Evaluation of Hand Tremor and Stable Kidney Transplant Patients When Switched From Prograf to LCP-Tacro. — 25.30; 19.96; -5.35 units on a scale — p=0.0048

Veloxis Pharmaceuticals Results May 2015 1.2% serious AE View details

Phase 3 N=199 A Simultaneous Treatment Regimen Compared to a Sequential Treatment Regimen With Ingenol Mebutate Gel 0.015% and 0.05% of Two Areas With Actinic Keratosis on Face/Scalp and Trunk/Extremities

Actinic Keratosis

Primary: Composite Local Skin Reaction (LSR) Score 3 Days After Treatment of Each Selected Treatment Area — 10.4; 9.7 units on a scale — p=0.13

LEO Pharma Results May 2015 3.5% serious AE View details

Phase 3 N=466 A Safety Study of Bimatoprost in Patients With Glaucoma or Ocular Hypertension

Glaucoma · Ocular Hypertension

Primary: Percentage of Patients With an Increase in Macroscopic Conjunctival Hyperemia in Either Eye — 34.3; 39.1 Percentage of Patients

Allergan Results May 2015 0.9% serious AE View details

Phase 3 N=223 Safety & Efficacy of a Single Dose of Sumatriptan Powder Delivered Intranasally With the Bi-directional Device in Adults With Acute Migraine

Migraine Headache

Primary: Headache Relief — 47; 73 participants

Optinose US Inc. Results May 2015 0.0% serious AE View details

Phase 3 N=107 Saracatinib and Paclitaxel in Platinum-resistant Ovarian Cancer

Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal Cancer

Primary: 6 Month Progression-free Survival Rate (PFS) (Based on Combined Response Evaluation Criteria In Solid Tumours (RECIST) v1.1 +/- Gynecologic Cancer Intergroup (GCIG)…

University College, London Results May 2015 55.8% serious AE View details

Phase 3 N=114 Irbesartan and Atenolol in Hypertensive Heart Disease

Hypertension

Primary: Changes in Left Ventricular Mass Index — -1; -9; -6; -14 g/m^2

Karolinska Institutet Results May 2015 8.8% serious AE View details

Phase 3 N=62 Cognitive Remediation With D-Cycloserine

Smoking Cessation

Primary: Effect of D-cycloserine + Cue-exposure Treatment on Continuous Abstinence From Tobacco Smoking. — 9; 30 percentage of participants

Massachusetts General Hospital Results May 2015 1.6% serious AE View details